Tremelimumab No Match vs Metastatic Melanoma Standard of Care

The anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody tremelimumab failed to achieve a significant improvement in survival among patients with metastatic melanoma compared with the standard of care treatments used in the comparator arm, according to the results of a phase III study.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

AbstractIntravascular dissemination of tumor cells is the accepted mechanism of cancer metastasis. However, the phenomenon of angiotropism, pericyte mimicry (PM), and extravascular migratory metastasis (EVMM) has questioned the concept that tumor cells metastasize exclusively via circulation within vascular channels. This new paradigm of cancer spread and metastasis suggests that metastatic cells employ embryonic mechanisms for attachment to the abluminal surfaces of blood vessels (angiotropism) and spread via continuous migration, competing with and replacing pericytes, i.e., pericyte mimicry (PM). This is an entirely ext...
Source: Angiogenesis - Category: Molecular Biology Source Type: research
Contributors : Pakavarin Louphrasitthiphol ; Colin R GodingSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe MITF and SOX10 transcription factors regulate the expression of genes important for melanoma proliferation, invasion and metastasis. Despite growing evidence of the contribution of long non-coding RNAs (lncRNAs) in melanoma and other cancers, their functions within MITF-SOX10 transcriptional programmes is poorly investigated. Here, we identify 245 candidate melanoma associated lncRNAs whose loci are co-occupied by MITF-SOX10 and are enriched at active enhancer-like regions. W...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
ConclusionsIn patients with RA, the relative increase in etanercept-associated risk of experiencing congestive heart failure, serious infection, non-melanoma skin cancer, or interstitial lung disease was similar between elderly and non-elderly.
Source: Drugs and Aging - Category: Geriatrics Source Type: research
Recently, immune checkpoint therapy was shown to be very effective in the treatment of several cancers by reactivating the immune system. This was also shown for hard to treat cancers such as melanoma and lung cancer. At the forefront of immune checkpoint therapy are antibodies targeting cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and the programmed cell death-1 (PD-1). However, clinical success of immune checkpoint inhibitors greatly varies between different cancer types, ranging from objective responses in 65-87% of Hodgkin lymphoma (HL) patients to around 30% in other malignancies [reviewed by [1 –3]].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research
AbstractNivolumab is a fully human monoclonal antibody that inhibits programmed cell death ‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐small cell lung cancer, renal cell carcinoma, or small cell lung cancer who rec eived nivolumab as monotherapy or in combination with ipilimumab or chemotherapy across 25 clinical studies. Nivolumab CL was similar across the tumor types examined; CL was higher for ipilimumab 1 mg/kg every 6 weeks (by 17%) and 3 mg/kg...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
AbstractIpilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time ‐varying clearance (CL) was assessed by a population pharmacokinetics (PPK) model developed using statistically significant covariates identified in a previous PPK analysis plus additional covariates. Data from 3,411 patients who received ipilimumab 0.3–10 mg/kg alone or in combination with niv olumab in 16 clinical trials were analyzed. Ipilimumab CL decreased over time; the ch...
Source: CPT: Pharmacometrics and Systems Pharmacology - Category: Drugs & Pharmacology Authors: Tags: ARTICLE Source Type: research
Publication date: Available online 9 November 2019Source: Materials Today CommunicationsAuthor(s): Felipe Alves Batista, Sabryna Brena Cunha Fontele, Lubna Karine Beserra Santos, Livia Alves Filgueiras, Steffane Quaresma Nascimento, João Marcelo de Castro e Sousa, Juan Carlos Ramos Gonçalves, Anderson Nogueira MendesAbstractThe development of systems for transport and release of drugs, also known as Drug delivery system (DDS), and are being used as strategies to combat cancer. These systems can maintain drug delivery at therapeutic levels and protect it from premature degradation in the biological environment...
Source: Materials Today Communications - Category: Materials Science Source Type: research
Publication date: Available online 8 November 2019Source: Artificial Intelligence in MedicineAuthor(s): Ni Zhang, Yi-Xin Cai, Yong-Yong Wang, Yi-Tao Tian, Xiao-Li Wang, Benjamin BadamiAbstractEarly detection of skin cancer is very important and can prevent some skin cancers, such as focal cell carcinoma and melanoma. Although there are several reasons that have bad impacts on the detection precision. Recently, the utilization of image processing and machine vision in medical applications is increasing. In this paper, a new image processing based method has been proposed for the early detection of skin cancer. The method ut...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Both cell adhesion and matrix metalloproteinase (MMP) activity depend on pH at the cell surface. By regulating extracellular juxtamembrane pH, the Na+/H+ exchanger NHE1 plays a significant part in human melanoma ...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
Farzaneh Ioannis P. Trougakos Wolfgang Voelter Meletios-Athanasios Dimopoulos Aristotelis Bamias Ourania Tsitsilonis Prothymosin α (proTα) and its C-terminal decapeptide proTα(100–109) were shown to pleiotropically enhance innate and adaptive immune responses. Their activities have been broadly studied in vitro, focusing primarily on the restoration of the deficient immunoreactivity of cancer patients’ leukocytes. Previously, we showed that proTα and proTα(100–109) act as danger-associated molecular patterns (DAMPs), ligate Toll-l...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Melanoma | Skin Cancer | Study